OIS@AAO
Aly1337 is a novel, small-molecule multi-kinase inhibitor that Allysta Pharmaceuticals Inc. is developing to treat glaucoma, said Henry Hsu, MD, Founder and CEO. Kinase, particularly…
Read MorePublicly traded Aerie Pharmaceuticals Inc. has two Rho kinase inhibitors, or ROCK inhibitors, in development, CEO Vicente Anido, Jr, PhD, reported Rhopressa which is in phase…
Read MoreONL Therapeutics Inc. is developing Met12, a small peptide inhibitor that uses a novel mechanism to attack Fas receptor apoptosis, which has a key role…
Read MoreKala Pharmaceutical Inc. is moving its proprietary Lotoprednol Etaobnate Mucus Penetrating Particle (LE-MPP) platform through a host of trials, Interim President and CBO Charlie McDermott…
Read MoreClinicians have few treatment options for dry AMD, but Translatum Medicus Inc., is working on an agent, TMi-018, for such an indication. President and CSO…
Read MorePanoptes Pharma GmhB is developing PP-001, a dihydroorotate dehydrogenase (DHODH) inhibitor for local treatments in ocular disease, Co-Founder and CEO Franz Obermayr, PhD, told the…
Read MoreModerator: Gilbert H. Kliman, MD Dr. Gil Kliman leads the medical device investment team at InterWest Partners and invests in a broad array of healthcare…
Read MoreSummit Co-Chair and Managing Director for InterWest Partners, Gilbert Kliman MD, captures the audience’s thoughts on commercialization strategies in Europe through a series of live…
Read MoreEmmett T. Cunningham Jr. MD PhD MPH, Partner at Clarus Ventures and Summit Chairman, delivers an overview of some ophthalmic highlights from 2013. Sharing key…
Read MoreKeynote: Sustaining Innovation in Ophthalmology – “A View From the Top” David E.I. Pyott, Chairman of the Board & CEO for Allergan, delivers a keynote…
Read MoreWilliam J. Link PhD, Managing Director for Versant Ventures, gives the audience at the 5th Annual Ophthalmology Innovation Summit a look into the returns on…
Read MorePrivate Funding and Exit Trends Jonathan Norris, Managing Director for SVB Capital, takes the stage to share the positive sentiments on the private markets. Highlighting…
Read More
SUBSCRIBE TO OIS NEWS
Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.
We respect your privacy and promise to never send you spam.
![OIS-ANTERIOR-NEW-DATE-750x420[4300]](https://ois.net/wp-content/uploads/2020/03/OIS-ANTERIOR-NEW-DATE-750x4204300.jpg "OIS-ANTERIOR-NEW-DATE-750x420[4300]")